vs
Side-by-side financial comparison of 4D Molecular Therapeutics, Inc. (FDMT) and Primis Financial Corp. (FRST). Click either name above to swap in a different company.
4D Molecular Therapeutics, Inc. is the larger business by last-quarter revenue ($85.1M vs $45.6M, roughly 1.9× Primis Financial Corp.). 4D Molecular Therapeutics, Inc. runs the higher net margin — 22.8% vs 16.0%, a 6.8% gap on every dollar of revenue. Over the past eight quarters, 4D Molecular Therapeutics, Inc.'s revenue compounded faster (5412.6% CAGR vs 13.0%).
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.
Primis Financial Corp is a U.S.-based financial holding company operating full-service banking subsidiaries. It provides a comprehensive range of financial solutions including personal and commercial deposit products, diverse loan facilities, mortgage services, and wealth management support, primarily serving retail and corporate customers across the U.S. mid-Atlantic region.
FDMT vs FRST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $85.1M | $45.6M |
| Net Profit | $19.4M | $7.3M |
| Gross Margin | — | — |
| Operating Margin | 17.3% | — |
| Net Margin | 22.8% | 16.0% |
| Revenue YoY | 8508900.0% | — |
| Net Profit YoY | 139.1% | 200.0% |
| EPS (diluted) | $0.43 | $0.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $45.6M | ||
| Q4 25 | $85.1M | $80.9M | ||
| Q3 25 | $90.0K | $41.0M | ||
| Q2 25 | $15.0K | $43.2M | ||
| Q1 25 | $14.0K | $58.7M | ||
| Q4 24 | $1.0K | $38.8M | ||
| Q3 24 | $3.0K | $37.3M | ||
| Q2 24 | $5.0K | $35.7M |
| Q1 26 | — | $7.3M | ||
| Q4 25 | $19.4M | $29.5M | ||
| Q3 25 | $-56.9M | $6.8M | ||
| Q2 25 | $-54.7M | $2.4M | ||
| Q1 25 | $-48.0M | $22.6M | ||
| Q4 24 | — | $-26.2M | ||
| Q3 24 | $-43.8M | $1.2M | ||
| Q2 24 | $-35.0M | $3.4M |
| Q1 26 | — | — | ||
| Q4 25 | 17.3% | 44.8% | ||
| Q3 25 | -67983.3% | 21.3% | ||
| Q2 25 | -396373.3% | 6.9% | ||
| Q1 25 | -383007.1% | 41.9% | ||
| Q4 24 | — | -123.0% | ||
| Q3 24 | -1704400.0% | -3.1% | ||
| Q2 24 | -849120.0% | 7.8% |
| Q1 26 | — | 16.0% | ||
| Q4 25 | 22.8% | 36.5% | ||
| Q3 25 | -63195.6% | 16.7% | ||
| Q2 25 | -364386.7% | 5.6% | ||
| Q1 25 | -342657.1% | 38.6% | ||
| Q4 24 | — | -100.3% | ||
| Q3 24 | -1461433.3% | 3.3% | ||
| Q2 24 | -699060.0% | 9.6% |
| Q1 26 | — | $0.30 | ||
| Q4 25 | $0.43 | $1.19 | ||
| Q3 25 | $-1.01 | $0.28 | ||
| Q2 25 | $-0.98 | $0.10 | ||
| Q1 25 | $-0.86 | $0.92 | ||
| Q4 24 | — | $-0.95 | ||
| Q3 24 | $-0.79 | $0.05 | ||
| Q2 24 | $-0.63 | $0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $402.7M | $159.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $505.7M | $427.2M |
| Total Assets | $566.7M | $4.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $159.9M | ||
| Q4 25 | $402.7M | $143.6M | ||
| Q3 25 | $305.1M | $63.9M | ||
| Q2 25 | $293.2M | $94.1M | ||
| Q1 25 | $321.4M | $57.0M | ||
| Q4 24 | $424.9M | $64.5M | ||
| Q3 24 | $501.9M | $77.3M | ||
| Q2 24 | $541.9M | $66.6M |
| Q1 26 | — | $427.2M | ||
| Q4 25 | $505.7M | $422.9M | ||
| Q3 25 | $369.0M | $382.2M | ||
| Q2 25 | $420.9M | $376.4M | ||
| Q1 25 | $469.7M | $375.6M | ||
| Q4 24 | $510.6M | $351.8M | ||
| Q3 24 | $552.9M | $381.0M | ||
| Q2 24 | $588.3M | $376.0M |
| Q1 26 | — | $4.3B | ||
| Q4 25 | $566.7M | $4.0B | ||
| Q3 25 | $424.0M | $4.0B | ||
| Q2 25 | $473.6M | $3.9B | ||
| Q1 25 | $515.7M | $3.7B | ||
| Q4 24 | $560.4M | $3.7B | ||
| Q3 24 | $604.0M | $4.0B | ||
| Q2 24 | $620.1M | $4.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.6M | — |
| Free Cash FlowOCF − Capex | $28.5M | — |
| FCF MarginFCF / Revenue | 33.5% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | 1.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-109.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $28.6M | $10.8M | ||
| Q3 25 | $-46.5M | $-11.4M | ||
| Q2 25 | $-43.4M | $-41.0M | ||
| Q1 25 | $-47.8M | $34.4M | ||
| Q4 24 | $-134.6M | $19.5M | ||
| Q3 24 | $-29.4M | $6.1M | ||
| Q2 24 | $-30.2M | $52.3M |
| Q1 26 | — | — | ||
| Q4 25 | $28.5M | $9.0M | ||
| Q3 25 | $-46.6M | — | ||
| Q2 25 | $-43.4M | — | ||
| Q1 25 | $-48.4M | — | ||
| Q4 24 | $-138.4M | $18.3M | ||
| Q3 24 | $-31.2M | — | ||
| Q2 24 | $-30.6M | — |
| Q1 26 | — | — | ||
| Q4 25 | 33.5% | 11.2% | ||
| Q3 25 | -51765.6% | — | ||
| Q2 25 | -289620.0% | — | ||
| Q1 25 | -345635.7% | — | ||
| Q4 24 | -13837100.0% | 47.3% | ||
| Q3 24 | -1038966.7% | — | ||
| Q2 24 | -611840.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 2.1% | ||
| Q3 25 | 101.1% | — | ||
| Q2 25 | 440.0% | — | ||
| Q1 25 | 4507.1% | — | ||
| Q4 24 | 378600.0% | 3.1% | ||
| Q3 24 | 59266.7% | 0.0% | ||
| Q2 24 | 6980.0% | 0.0% |
| Q1 26 | — | — | ||
| Q4 25 | 1.47× | 0.36× | ||
| Q3 25 | — | -1.67× | ||
| Q2 25 | — | -16.82× | ||
| Q1 25 | — | 1.52× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 4.93× | ||
| Q2 24 | — | 15.21× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FDMT
Segment breakdown not available.
FRST
| Net Interest Income | $32.1M | 70% |
| Noninterest Income | $13.6M | 30% |
